Fact CheckerSign in

NCT06566430Recruiting

PrEP My Way: A Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women

Source: ClinicalTrials.gov · Last updated 22 Apr 2026

Brief summary (registry, in English)

PrEP My Way is a novel PrEP delivery system consisting of clinic-based PrEP initiation, followed by peer-delivered kits for HIV self-testing, PrEP refills, vaginal swabs for gonorrhea and chlamydia self-sampling, pregnancy tests, and contraception refills, if desired. Based on Social Cognitive Theory, the overall hypothesis is that PrEP My Way will overcome critical stigma and structural barriers that currently limit PrEP use and thus empower young women to promote their sexual health. Preliminary testing of PrEP My Way in Kisumu, Kenya found it to be highly feasible and acceptable, but PrEP use as an oral medication was lower than expected. Now that newer PrEP formulations are becoming available, the team is adding choice of PrEP formulation (i.e., oral tenofovir/emtricitabine, injectable cabotegravir-long acting \[CAB-LA\], or dapivirine ring) as well as choice of adherence support from peers (e.g., SMS \[short message service\], routine check-ins and/or WhatsApp groups) to the intervention. The study team will then test the effectiveness of the augmented PrEP My Way intervention (with and without testing for gonorrhea and chlamydia due to cost concerns) on PrEP persistence in women with ongoing HIV prevention needs (i.e., self-reported desire for PrEP, self-reported HIV risk, condomless sex, and/or multiple sexual partners). The team will also track implementation, service, and client metrics per Proctor's framework and determine cost-effectiveness of the intervention

Status (registry)
Recruiting
Study type
Interventional
Enrollment
500 (estimated)
First submitted
19 Aug 2024
Start date
3 Mar 2025
Primary completion date
1 May 2028
Lead sponsor
Massachusetts General Hospital
Diseases
HIV
NCT number
NCT06566430

What you commit to

  • Study type: Interventional
  • Planned participants: 500
  • From 3 Mar 2025 to the primary completion date, 1 May 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • inability to provide informed consent (e.g., intoxication)

Who the study is looking for

  • young women (age 16-24 years)
  • initiating PrEP at the recruitment site (this criterion subsumes all necessary safety assessments for starting PrEP, including HIV-negative status and for those taking FTC/TDF normal renal function and lack of Hepatitis B infection)
  • resident in Kisumu County
  • phone ownership
  • ability to understand KiSwahili, DhoLuo, and/or English

Age in the registry: 16 years to 24 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Kenya Medical Research Institute
Coordinator of this site? Confirm its status
KisumuKenyaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.